LeWitt Peter A
Departments of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, MI 48322, USA.
Clin Neuropharmacol. 2013 May-Jun;36(3):92-3. doi: 10.1097/WNF.0b013e318290cd41.
Although tetrabenazine is widely used as an effective treatment for chorea and other hyperkinetic movement disorders, it has been associated with rare instances of parkinsonism and acute dystonic reactions. There have been no prior reports of tardive dyskinesia with this drug.
Case report.
Generalized choreiform dyskinesia developed after 10 months of conventional-dosage tetrabenazine treatment, persisting for several weeks after the drug was discontinued.
As might be anticipated from its pharmacological profile, tetrabenazine has the potential to cause tardive dyskinesia. Such an occurrence may be difficult to detect in a clinical population already affected with involuntary movements.
尽管丁苯那嗪被广泛用作治疗舞蹈症和其他运动亢进性运动障碍的有效药物,但它与罕见的帕金森综合征和急性肌张力障碍反应有关。此前尚无关于该药物导致迟发性运动障碍的报道。
病例报告。
在常规剂量的丁苯那嗪治疗10个月后出现全身性舞蹈样运动障碍,停药后持续数周。
从其药理特性来看,丁苯那嗪有可能导致迟发性运动障碍。在已经患有不自主运动的临床人群中,这种情况可能难以察觉。